<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898348</url>
  </required_header>
  <id_info>
    <org_study_id>KBL-CURE-2020-03</org_study_id>
    <nct_id>NCT04898348</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KoBioLabs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KoBioLabs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to investigate efficacy and safety of KBL697 in patients with mild to&#xD;
      moderate active ulcerative colitis. KBL697 has been developed as a potential new treatment&#xD;
      for ulcerative colitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients with Clinical Remission</measure>
    <time_frame>Week 9</time_frame>
    <description>Proportion of Patients with Clinical Remission at Week 9</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Partial Mayo Score</measure>
    <time_frame>Week 9</time_frame>
    <description>Change from baseline in Partial Mayo Score at Week 9 Minimum value: 0, Maximum value: 9, higher score mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portion of patients with Endoscopic subscore change</measure>
    <time_frame>Week 9</time_frame>
    <description>Portion of patients with endoscopic subscore decrease to ≥ 1 at Week 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in C-reactive Protein</measure>
    <time_frame>Week 9</time_frame>
    <description>Change from baseline in concentration of C-reactive Protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Fecal Calprotectin</measure>
    <time_frame>Week 9</time_frame>
    <description>Change from baseline in concentration of fecal Calprotectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Inflammatory Bowel Disease Questionnaire score</measure>
    <time_frame>Week 9</time_frame>
    <description>Changes from baseline in Inflammatory Bowel Disease Questionnaire score Minimum value: 0, Maximum value: 224, higher score mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Histologic Disease Activity</measure>
    <time_frame>Week 9</time_frame>
    <description>Change from baseline in histologic disease activity measured by Geboes score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measure through incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Week 13</time_frame>
    <description>Occurrence of TEAEs, treatment-related TEAEs, TEAEs by severity (mild/moderate/severe), serious TEAEs, TEAEs leading to dose adjustment, treatment termination, or death will be summarized by actual treatment groups respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Placebo (after Vancomycin pre-treatment)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 capsules twice a day dosing of Placebo (after Vancomycin pre-treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KBL697 (after Vancomycin pre-treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules twice a day dosing of KBL697 (after Vancomycin pre-treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin Pre-Treatment</intervention_name>
    <description>Four times per day dosing of Vancomycin pre-treatment</description>
    <arm_group_label>KBL697 (after Vancomycin pre-treatment)</arm_group_label>
    <arm_group_label>Placebo (after Vancomycin pre-treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KBL697</intervention_name>
    <description>3 capsules twice a day dosing of KBL697</description>
    <arm_group_label>KBL697 (after Vancomycin pre-treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 capsules twice a day dosing of Placebo</description>
    <arm_group_label>Placebo (after Vancomycin pre-treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has an established diagnosis of ulcerative colitis for at least 3 months prior&#xD;
             to Screening&#xD;
&#xD;
          -  Patient has active mild to moderate ulcerative colitis at Visit 2&#xD;
&#xD;
          -  Patient is taking at least one of the following oral medication: 5-ASA,&#xD;
             Corticosteroids, Immunomodulators&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has a possible or confirmed diagnosis of Crohn's Disease or other forms of&#xD;
             inflammatory bowel disorders&#xD;
&#xD;
          -  Patient has a persistent fever of ≥ 38.3°C&#xD;
&#xD;
          -  Patient has current signs or symptoms of infection&#xD;
&#xD;
          -  Patient has any immunosuppressant condition&#xD;
&#xD;
          -  Patient has a known malignancy within 5 years prior to Screening&#xD;
&#xD;
          -  Patient has a known allergy or intolerance to vancomycin&#xD;
&#xD;
          -  Patient has any contraindication for use of vancomycin&#xD;
&#xD;
          -  Patient who has a medical history of drug abuse or alcohol abuse&#xD;
&#xD;
          -  Patient who, in the opinion of the Investigator, has a clinically significant&#xD;
             co-morbid disease&#xD;
&#xD;
          -  Patient has hepatic failure&#xD;
&#xD;
          -  Patient is pregnant or plans a pregnancy within the study period&#xD;
&#xD;
          -  Patient has no previous history of treatment for ulcerative colitis (treatment-naïve&#xD;
             patient)&#xD;
&#xD;
          -  Patient has ongoing or failed treatment for ulcerative colitis with calcineurin&#xD;
             inhibitor&#xD;
&#xD;
          -  Patient has received biologic medication&#xD;
&#xD;
          -  Patient has received antibiotics within 4 weeks prior to Visit 2&#xD;
&#xD;
          -  Patient is unable to stop previous antibiotics treatment during study period&#xD;
&#xD;
          -  Patient has received probiotics within 2 weeks prior to Visit 2&#xD;
&#xD;
          -  Patient with history of major surgery in any region of the gastrointestinal tract&#xD;
&#xD;
          -  Patient has received any investigational product or participated in another clinical&#xD;
             trial&#xD;
&#xD;
          -  Patient has a stool culture or other examination positive for an enteric pathogen&#xD;
&#xD;
          -  Patient tests positive for CMV by PCR test at Screening&#xD;
&#xD;
          -  Patient tests positive for HIV at Screening&#xD;
&#xD;
          -  Exclusion criteria based on results of Hepatitis B at Screening&#xD;
&#xD;
          -  Exclusion criteria based on results of Hepatitis C at Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arial (Jinyoung) Bai</last_name>
    <phone>+82 2 8889964</phone>
    <email>jinyoung.bai@kobiolabs.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microbiome</keyword>
  <keyword>KBL697</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

